ARVINAS, INC. — Form 8-K
Filed November 3, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 48/100
What the filing says
Arvinas reported Q3 2026 results with cash/equivalents/securities of $558.9M (down from $685.4M at 12/31/2025; $126.5M burn in 9 months). Key developments: initiated dosing in ARV-6723 (HPK1, immuno-oncology) Phase 1/2 trial; presented ARV-102 (LRRK2, neurology) Phase 1 data showing oculomotor improvements and biomarker engagement in Parkinson's disease; advanced ARV-393 (BCL6, hematology) dose escalation and ARV-027 (polyQ-AR, SBMA) enrollment. Revenue collapsed to $0.5M Q3 2026 vs. $41.9M Q3 2025 post-Pfizer Vepdegestrant deferred revenue recognition; R&D spend decreased to $46.9M Q3 2026 vs. $64.7M Q3 2025, driven by ARV-471 wind-down offset partially by new program spending. Company projects cash sufficiency into 2H 2028.
Why this rating
Operational progress on pipeline is routine for clinical-stage biotech; cash burn ($126.5M/9mo ≈ 27% of market cap annually) is material but manageable with 2028 runway. No transformational event.
See more from November 3, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.